WO2008156094A1 - ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 - Google Patents

ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 Download PDF

Info

Publication number
WO2008156094A1
WO2008156094A1 PCT/JP2008/061087 JP2008061087W WO2008156094A1 WO 2008156094 A1 WO2008156094 A1 WO 2008156094A1 JP 2008061087 W JP2008061087 W JP 2008061087W WO 2008156094 A1 WO2008156094 A1 WO 2008156094A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
active ingredient
inhibitor containing
pyridazinone derivative
pde inhibitor
Prior art date
Application number
PCT/JP2008/061087
Other languages
English (en)
French (fr)
Inventor
Yasushi Kohno
Koji Ochiai
Satoshi Takita
Akihiko Kojima
Tomohiko Eiraku
Tetsuya Kishi
Original Assignee
Kyorin Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co., Ltd. filed Critical Kyorin Pharmaceutical Co., Ltd.
Priority to JP2009520496A priority Critical patent/JPWO2008156094A1/ja
Priority to CA002692248A priority patent/CA2692248A1/en
Priority to EP08765704A priority patent/EP2168959A1/en
Priority to US12/452,172 priority patent/US20100160335A1/en
Publication of WO2008156094A1 publication Critical patent/WO2008156094A1/ja

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

ホスホジエステラーゼ阻害作用を有する医薬品として有用な下記一般式(1)で表される新規ピリダジノン誘導体を提供すること。
PCT/JP2008/061087 2007-06-19 2008-06-18 ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤 WO2008156094A1 (ja)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2009520496A JPWO2008156094A1 (ja) 2007-06-19 2008-06-18 ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤
CA002692248A CA2692248A1 (en) 2007-06-19 2008-06-18 Pyridazinone derivative and pde inhibitor containing the same as active ingredient
EP08765704A EP2168959A1 (en) 2007-06-19 2008-06-18 Pyridazinone derivative and pde inhibitor containing the same as active ingredient
US12/452,172 US20100160335A1 (en) 2007-06-19 2008-06-18 Pyridazinone derivative and pde inhibitor containing the same as active ingredient

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007-160955 2007-06-19
JP2007160955 2007-06-19

Publications (1)

Publication Number Publication Date
WO2008156094A1 true WO2008156094A1 (ja) 2008-12-24

Family

ID=40156253

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/061087 WO2008156094A1 (ja) 2007-06-19 2008-06-18 ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤

Country Status (5)

Country Link
US (1) US20100160335A1 (ja)
EP (1) EP2168959A1 (ja)
JP (1) JPWO2008156094A1 (ja)
CA (1) CA2692248A1 (ja)
WO (1) WO2008156094A1 (ja)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117926A1 (en) * 2009-04-07 2010-10-14 Schering Corporation Substituted triazolopyridines and analogs thereof
JP2012512192A (ja) * 2008-12-19 2012-05-31 レオ ファーマ アクティーゼルスカブ 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体
EP2719686A1 (en) * 2010-03-12 2014-04-16 Nippon Soda Co., Ltd. Process to halogenate a picoline derivative
JP2019506432A (ja) * 2016-03-04 2019-03-07 大塚製薬株式会社 5−メチル−6−フェニル−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2069312T3 (da) * 2006-07-25 2013-02-04 Cephalon Inc Pyridazinonderivater
RS56654B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
WO2012104782A1 (en) 2011-02-03 2012-08-09 Lupin Limited Pyrrole derivatives used as modulators of alpha7 nachr
BR112013025128A2 (pt) 2011-03-31 2017-02-14 Lupin Ltd derivados de pirrol como moduladores de receptor de acetilcolina nicotínico para uso no tratamento de distúrbios neurodegenenerativos tal como doença de alzheimer e doença de parkinson
DE202012013074U1 (de) 2011-09-16 2014-10-29 Gilead Pharmasset Lcc Zusammensetzungen zur Behandlung von HCV
CN104144682A (zh) 2013-01-31 2014-11-12 吉利德法莫赛特有限责任公司 两个抗病毒化合物的联用制剂
ES2900570T3 (es) 2013-08-27 2022-03-17 Gilead Pharmasset Llc Formulación de combinación de dos compuestos antivirales
CN104478809B (zh) * 2014-11-14 2016-08-17 成都新恒创药业有限公司 一种左西孟旦杂质及其制备和检测方法
CN104530113A (zh) * 2014-12-22 2015-04-22 上海树农化工有限公司 邻氟苯甲酸类化合物及其制备方法
CN106905233A (zh) * 2016-08-31 2017-06-30 湖南大学 一种5‑位炔基化8‑酰胺基喹啉类化合物及其一锅法制备方法
CN106938985B (zh) * 2016-08-31 2020-05-05 湖南大学 一种5-位烯基化8-酰胺基喹啉类化合物及其一锅法制备方法
CN106938984B (zh) * 2016-08-31 2020-05-05 湖南大学 一种5-位取代芳基化/杂环化8-酰胺基喹啉类化合物及其一锅法制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン-4-イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤
JP2007119397A (ja) * 2005-10-28 2007-05-17 Kyorin Pharmaceut Co Ltd ピラゾロピリジン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤
JP2008024599A (ja) * 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするpde阻害剤及び医薬
WO2008029882A1 (fr) * 2006-09-07 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Dérivé de 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone, sel d'addition de celui-ci et inhibiteur de la pde comprenant le dérivé ou le sel en tant que matière active
JP2008063265A (ja) * 2006-09-06 2008-03-21 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン-4-イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤
JP2007119397A (ja) * 2005-10-28 2007-05-17 Kyorin Pharmaceut Co Ltd ピラゾロピリジン誘導体とその付加塩及びそれらを有効成分とするpde阻害剤
JP2008024599A (ja) * 2006-07-18 2008-02-07 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体、それらを有効成分とするpde阻害剤及び医薬
JP2008063265A (ja) * 2006-09-06 2008-03-21 Kyorin Pharmaceut Co Ltd ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤
WO2008029882A1 (fr) * 2006-09-07 2008-03-13 Kyorin Pharmaceutical Co., Ltd. Dérivé de 2-alkyl-6-(pyrazolopyridin-4-yl)pyridazinone, sel d'addition de celui-ci et inhibiteur de la pde comprenant le dérivé ou le sel en tant que matière active

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VAN DER MEY ET AL.: "Synthesis and Structure-Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids: A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents", JOURNAL OF MEDICINAL CHEMISTRY, vol. 46, no. 10, 2003, pages 2008 - 2016, XP008126345 *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012512192A (ja) * 2008-12-19 2012-05-31 レオ ファーマ アクティーゼルスカブ 皮膚疾患の処置のためのホスホジエステラーゼ阻害薬としてのトリアゾロピリジン誘導体
WO2010117926A1 (en) * 2009-04-07 2010-10-14 Schering Corporation Substituted triazolopyridines and analogs thereof
TWI397530B (zh) * 2009-04-07 2013-06-01 Merck Sharp & Dohme 經取代的***并吡啶及其類似物
US8685967B2 (en) 2009-04-07 2014-04-01 Merck Sharp & Dohme Corp. Substituted triazolopyridines and analogs thereof
EP2719686A1 (en) * 2010-03-12 2014-04-16 Nippon Soda Co., Ltd. Process to halogenate a picoline derivative
US8841458B2 (en) 2010-03-12 2014-09-23 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US8962848B2 (en) 2010-03-12 2015-02-24 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US9000178B2 (en) 2010-03-12 2015-04-07 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US9012653B2 (en) 2010-03-12 2015-04-21 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
US9018385B2 (en) 2010-03-12 2015-04-28 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
JP2019506432A (ja) * 2016-03-04 2019-03-07 大塚製薬株式会社 5−メチル−6−フェニル−4,5−ジヒドロ−2h−ピリダジン−3−オン誘導体
US10611731B2 (en) 2016-03-04 2020-04-07 Otsuka Pharmaceutical Co., Ltd. 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative

Also Published As

Publication number Publication date
EP2168959A1 (en) 2010-03-31
JPWO2008156094A1 (ja) 2010-08-26
US20100160335A1 (en) 2010-06-24
CA2692248A1 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするpde阻害剤
WO2006053255A3 (en) Novel betulin derivatives, preparation thereof and use thereof
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2005074603A3 (en) Aminobenzoxazoles as therapeutic agents
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
WO2009107850A3 (en) Fused heterocyclic derivative and use thereof
WO2007148185A3 (en) Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
WO2008011130A8 (en) Amide compounds
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
WO2009060835A8 (ja) 新規ユビキリン結合性小分子
WO2007135527A3 (en) Benzimidazolyl compounds
WO2007072153A3 (en) Carbonylamino pyrrolopyrazoles, potent kinase inhibitors
WO2008096841A1 (ja) 二量化シクロ誘導体
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2009082134A3 (en) Dipeptidyl peptidase-iv inhibiting compounds, methods of preparing the same, and pharmaceutical compositions containing the same as active agent
WO2009051119A1 (ja) ピリミジルインドリン化合物
WO2005085236A3 (en) Caspase inhibitors and uses thereof
WO2007017728A3 (en) Novel heterocyclic compounds
WO2009020137A1 (ja) アミノピラゾールアミド誘導体
TN2012000092A1 (en) Therapeutic agent for mood disorders
WO2009038412A3 (en) Beta-secretase inhibiting compounds
WO2007064719A3 (en) Formulations of quinolinones
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2009051223A1 (ja) 白内障処置のための医薬組成物
WO2007068728A3 (en) N-substituted pyrrolopyridinones active as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08765704

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009520496

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2692248

Country of ref document: CA

Ref document number: 2008765704

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12452172

Country of ref document: US